Stockscreener 앱 받기
6.07
1.46%
-0.09
시장 영업 전:
6.10
0.03
+0.49%
전일 마감가:
$6.16
열려 있는:
$6.08
하루 거래량:
1.22M
Relative Volume:
0.91
시가총액:
$395.65M
수익:
$65,400
순이익/손실:
$-46.34M
주가수익비율:
-6.5978
EPS:
-0.92
순현금흐름:
$-38.74M
1주 성능:
-17.30%
1개월 성능:
-41.41%
6개월 성능:
-25.06%
1년 성능:
+45.56%
1일 변동 폭
$5.94
$6.18
1주일 범위
$5.94
$7.60
52주 변동 폭
$3.61
$13.85
CorMedix Inc Stock (CRMD) Company Profile
명칭
CorMedix Inc
전화
908-517-9500
주소
400 Connell Drive, 5th Floor, Suite 5000, Berkeley Heights, NJ
CRMD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRMD
CorMedix Inc
|
6.07 | 395.65M | 65,400 | -46.34M | -38.74M | -0.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.74 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
617.00 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
567.09 | 34.59B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
255.76 | 33.10B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
271.04 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
CorMedix Inc Stock (CRMD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-07 | 개시 | Leerink Partners | Outperform |
| 2025-01-13 | 개시 | D. Boral Capital | Buy |
| 2024-08-26 | 개시 | Rodman & Renshaw | Buy |
| 2023-08-10 | 개시 | RBC Capital Mkts | Outperform |
| 2021-02-17 | 개시 | Needham | Buy |
| 2020-09-29 | 개시 | JMP Securities | Mkt Outperform |
| 2020-09-21 | 개시 | Truist | Buy |
| 2019-12-18 | 개시 | B. Riley FBR | Buy |
| 2019-03-26 | 재확인 | H.C. Wainwright | Buy |
| 2018-12-06 | 개시 | ROTH Capital | Buy |
| 2017-09-25 | 재확인 | H.C. Wainwright | Buy |
| 2017-08-10 | 재확인 | Rodman & Renshaw | Buy |
| 2017-05-05 | 재확인 | Rodman & Renshaw | Buy |
| 2016-11-11 | 재확인 | FBR & Co. | Outperform |
| 2016-03-17 | 재확인 | FBR Capital | Outperform |
| 2016-03-03 | 개시 | FBR Capital | Outperform |
| 2015-11-16 | 재확인 | ROTH Capital | Neutral |
| 2015-10-29 | 재확인 | ROTH Capital | Neutral |
| 2015-05-06 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2014-12-08 | 재확인 | ROTH Capital | Buy |
| 2011-10-03 | 다운그레이드 | Maxim Group | Buy → Hold |
모두보기
CorMedix Inc 주식(CRMD)의 최신 뉴스
CorMedix Inc. (NASDAQ:CRMD) Q4 2024 Earnings Call Transcript - Insider Monkey
CorMedix Inc. Reports Record Q4 Earnings and Growth - TipRanks
CorMedix: A Fair-Priced Biotech Company With A Bright Future - Seeking Alpha
CORMEDIX ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
CORMEDIX ALERT: Bragar Eagel & Squire, P.C. is Investigating CorMedix Inc. on Behalf of ... - Bluefield Daily Telegraph
Institutions along with individual investors who hold considerable shares inCorMedix Inc. (NASDAQ:CRMD) come under pressure; lose 35% of holdings value - Yahoo Finance
CorMedix Inc.'s (NASDAQ:CRMD) 35% loss last week hit both individual investors who own 56% as well as institutions - simplywall.st
CorMedix targets $50M-$60M revenue for H1 2025 with DefenCath growth - MSN
Lost Money on CorMedix Inc.(CRMD)? Contact Levi & Korsinsky Regarding an Ongoing Investigation - ACCESS Newswire
Kirby McInerney LLP Announces Investigation Against CorMedix Inc. (CRMD) on Behalf of Investors - GlobeNewswire
The Hidden Risks Behind CorMedix's First Profitable Quarter (NASDAQ:CRMD) - Seeking Alpha
CorMedix Inc (NASDAQ:CRMD) Order Delay - FXDailyReport.Com
Long Term Trading Analysis for (CRMD) - news.stocktradersdaily.com
INVESTOR ALERT: Investigation of CorMedix Inc. (CRMD) Announced by Holzer & Holzer, LLC - GlobeNewswire
Cormedix Inc (CRMD) Q4 2024 Earnings Call Highlights: A Profitable Quarter Amidst Strategic ... By GuruFocus - Investing.com Canada
CorMedix Inc. Achieves Profitability with DefenCath Launch - TipRanks
Rodman & Renshaw reiterates CorMedix stock Buy rating, $20 target By Investing.com - Investing.com Australia
CorMedix: Q4 Earnings Snapshot - MySA
Rodman & Renshaw reiterates CorMedix stock Buy rating, $20 target - Investing.com
CorMedix (CRMD) Q4 2024 Earnings Call Transcript - AOL.com
CorMedix earnings beat by $0.05, revenue topped estimates - Investing.com Canada
Needham Cuts CorMedix's Price Target to $12 from $18, Keeps Buy Rating - MarketScreener
CorMedix Stock Loses Almost A Third Of Its Market Cap After Downbeat H1 Revenue Outlook – But Retail Shrugs It - Asianet Newsable
Cormedix: Positive Outlook with Strategic Advancements and Strong Financial Performance - TipRanks
CorMedix Inc. (CRMD) Takes a Hit: What’s Behind the 31% Plunge? - RagingBull
Nasdaq Gains 50 Points; US New Home Sales Rise In February - Benzinga
CorMedix Stock Loses Almost A Third Of Its Market Cap After Downbeat H1 Revenue Outlook – But Retail Shrugs It Off - MSN
Earnings call transcript: CorMedix Q4 2024 reports first profit, stock plunges - Investing.com Australia
CorMedix shares tumble after order delay By Investing.com - Investing.com Philippines
CorMedix shares tumble after order delay - Investing.com
Earnings call transcript: CorMedix Q4 2024 reports first profit, stock plunges By Investing.com - Investing.com South Africa
CorMedix Dives on Results - Baystreet.ca
CorMedix Inc reports results for the quarter ended December 31Earnings Summary - TradingView
CorMedix Q4 Swings To Profit, Stock Down In Pre-market - Nasdaq
CorMedix Inc. Provides Preliminary Earnings Guidance for the First Half of 2025 - MarketScreener
CorMedix (CRMD) Q4 Earnings and Revenues Beat Estimates - Yahoo Finance
CORMEDIX Earnings Results: $CRMD Reports Quarterly Earnings - Nasdaq
CorMedix Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - The Manila Times
CorMedix Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - Marketscreener.com
CorMedix Hits Major Milestone: First-Ever Profitable Quarter Signals Strong Growth Ahead - Stock Titan
CorMedix Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call - Benzinga
CORMEDIX Earnings Preview: Recent $CRMD Insider Trading, Hedge Fund Activity, and More - Nasdaq
CorMedix Inc expected to post earnings of 14 cents a shareEarnings Preview - TradingView
CRMD INVESTOR NOTICE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages CorMedix Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important September 20 Deadline in Securities Class Action – CRMD - Business Wire
CorMedix Inc. to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 25, 2025 - The Manila Times
CorMedix Inc. to Announce Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025 - Nasdaq
Cormedix Inc. To Report Fourth Quarter And Full Year 2024 Financial Results And Provide A Corporate Update On March 25, 2025 - MENAFN.COM
CorMedix Inc (CRMD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.89%
0.13%
자본화:
|
볼륨(24시간):